DBV Technologies S.A.
DBVTDBV Technologies S.A. is a biopharmaceutical company focused on developing and commercializing innovative immunotherapy solutions for the treatment of food allergies. The company's flagship product, Viaskin, uses a patch-based delivery system aimed at desensitizing patients to specific allergens, particularly peanut allergies. Founded in France, DBV Technologies aims to address unmet medical needs through its proprietary epicutaneous immunotherapy platform.
Company News
DBV Technologies announced €166.7 million in gross proceeds from the full exercise of ABSA and BS warrants issued in March 2025. The company states it is sufficiently funded to support operations and commercial preparedness for a potential U.S. launch of VIASKIN® Peanut patch in children aged 4-7 years, contingent on regulatory approval. The w...
DBV Technologies announced it has received €166.7 million in gross proceeds from the full exercise of subscription warrants issued in March 2025. The company now has sufficient funds to support operations and commercial preparation for the potential U.S. launch of VIASKIN Peanut patch for children aged 4-7, pending regulatory approval. The comp...
DBV Technologies published updated information on its capital structure as of December 31, 2025, reporting 235,670,864 total shares and voting rights. The company also released a half-year report on its liquidity contract with ODDO BHF. The disclosure was made to comply with AMF regulations and corrected a previous publication from January 5, 202...
DBV Technologies disclosed its total number of shares and voting rights as of December 31, 2025, reporting 235,670,864 total shares with 235,596,284 net voting rights. The company also published a half-year report on its liquidity contract with ODDO BHF. The disclosure was updated to account for earlier exercise of securities instruments related ...
DBV Technologies released its half-year liquidity report for the period ending December 31, 2025, showing 74,580 shares and €527,891.63 in the liquidity account with ODDO BHF. The company executed 1,658 buy and 1,867 sales transactions, trading approximately 1.5 million shares on purchases and 1.6 million shares on sales. DBV Technologies conti...
